- Price
- $135.25
- Day
- +3.13%
- Mkt Cap
- $167.92B
- 52W Range
- $108.46 – $157.29
- Volume
- 10.08M
- Beta
- 0.34
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Total Product Sales (excluding Veklury): $7.6 billion, up 10% year-over-year.Total Product Sales (including Veklury): $7.6 billion, up 8% year-over-year.HIV Sal
Read full article
On August 4, 2026, Gilead Sciences Inc (GILD) released its 8-K filing detailing financial results for the second quarter of 2026, revealing a notable increase i
Read full article
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.
Read full article
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Read full article
Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of acquisitions.
Read full article
Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and increased its expected HIV growth rate, while reporting a quarterly non-GAAP loss driven by acquisition-related research and development charges.
Read full article
Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have bee
Read full article
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Dan.
Read full article
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea.
Read full article
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Read full article
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.
Read full article